Mechanisms of anosmia and brain infection in a genetic mouse model of COVID-19
Project Number5R01DC020980-02
Former Number1R01DC020980-01
Contact PI/Project LeaderMILLAR, SARAH E.
Awardee OrganizationICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Description
Abstract Text
Project Summary/Abstract
Infection of the olfactory epithelium in COVID-19 patients is thought to underlie loss of smell (anosmia), a
pathognomonic symptom that can be long-term in some patients, significantly affecting quality of life. The
olfactory epithelium is also believed to be a major entry point for systemic SARS-CoV-2 infection, which can
result in neurological as well as respiratory symptoms. Wild-type SARS-CoV-2 cannot bind the mouse ACE2
receptor, and existing human ACE2 (hACE2)-expressing mouse models either do not permit conditional
analysis or do not confer severe illness after infection. Due to the lack of genetically manipulable models that
display severe disease, the infected cell types responsible for acute and long-term anosmia, and the route(s)
by which the virus penetrates the brain, have not been definitively identified. To address these gaps in
knowledge and test cell type-specific requirements for COVID-19-related pathologies we generated conditional
hACE2fl knockin mice that express hACE2 in similar cell types to humans. hACE2fl mice nasally inoculated with
a high dose of wild-type SARS-CoV-2 display initial infection of olfactory epithelium and rapidly develop
anosmia. This is followed by infection of neurons in the olfactory bulb and brain, which is associated with
lethality and requires neuronal hACE2 expression. Importantly, specific destruction of olfactory epithelium via
methimazole treatment prevents olfactory bulb and brain infection and lethality, identifying the olfactory
epithelium as an essential gateway to CNS infection. hACE2fl mice inoculated with a low dose of wild-type
SARS-CoV-2 show reversible disease and survive, but a subset displays a long-term decrease in odor
sensitivity (hyposmia) like that observed in humans. We propose to use hACE2fl mice to provide definitive
genetic evidence for cellular mechanisms of short- and long-term loss of smell and identify the pathways for
brain infection during COVID-19. These studies are expected to complement existing descriptive human
studies to identify causal pathogenic mechanisms and preventative and therapeutic targets. Three specific
aims will be pursued: (i) define the cellular requirements for acute loss of smell; (ii) determine the mechanisms
of long-term hyposmia; and (iii) uncover the cellular mechanisms of olfactory bulb and brain infection.
Public Health Relevance Statement
Project Narrative
Loss of smell and other neurological symptoms are prevalent in COVID-19 disease and can be long-lasting,
significantly impairing quality of life; however, the underlying cellular mechanisms are poorly defined. We will
use a new, genetically manipulatable mouse model that is susceptible to SARS-CoV-2 infection to delineate
the mechanisms that underly acute and long-term loss of smell and identify the routes by which the virus can
invade the brain.
National Institute on Deafness and Other Communication Disorders
CFDA Code
173
DUNS Number
078861598
UEI
C8H9CNG1VBD9
Project Start Date
05-December-2023
Project End Date
30-November-2028
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$622,679
Direct Costs
$466,867
Indirect Costs
$155,812
Year
Funding IC
FY Total Cost by IC
2025
National Institute on Deafness and Other Communication Disorders
$622,679
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DC020980-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DC020980-02
Patents
No Patents information available for 5R01DC020980-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DC020980-02
Clinical Studies
No Clinical Studies information available for 5R01DC020980-02
News and More
Related News Releases
No news release information available for 5R01DC020980-02
History
No Historical information available for 5R01DC020980-02
Similar Projects
No Similar Projects information available for 5R01DC020980-02